Citations

Showing 10 of 108083 citations.

Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B
Perrillo, Robert P., Fried, Michael, Khalili, Mandana , Lau, Daryl , Sterling, Richard K. , Bisceglie, Adrian M. Di , Lisker‐Melman, Mauricio , Cooper, Stewart , Chung, Ray, Patel, Keyur , Roberts, Lewis R. , Belle, Steven H., Janssen, Harry L.A. , Roberts, Lewis R , Khalili, Mandana , Terrault, Norah A. , Lok, Anna S. , Wahed, Abdus S. , Ghany, Marc G. , Wong, David

Mayo Clinic

American Journal of Gastroenterology | January 4, 2023 | Volume: 118 | Issue: 7 | Pages: 1214-1225

10.14309/ajg.0000000000002125 | PMID 36599136 Get It

INTRODUCTION: Hepatitis B surface antigen (HBsAg) loss is associated with improved long-term outcomes of patients with chronic hepatitis B but is infrequently achieved with current monotherapies. We assessed whether combination strategies that included treatment withdrawal enhanced HBsAg loss. METHODS: A randomized (1:1) trial of tenofovir disoproxil fumarate (TDF) for 192 weeks with or without peginterferon (PegIFN) alfa-2a for the first 24 weeks, followed by withdrawal of TDF at week 192 with 48 weeks of off-treatment follow-up to week 240. The primary end point was HBsAg loss at week 240. RESULTS: Of 201 participants (52% HBeAg positive, 12%/6% genotype A/A2, 7% cirrhosis) randomized to TDF + PegIFN (n = 102) or TDF alone (n = 99), 6 participants had lost HBsAg at the end of the treatment phase (week 192), 5 (5.3%) in the combination group, and 1 (1.0%) in the TDF alone group ( P = 0.09). By week 240, 9 participants had cleared HBsAg, 5.3% in combination, and 4.1% in monotherapy arms ( P = 0.73). HBsAg decline and loss occurred earlier with TDF + PegIFN than TDF, with a ≥1-logIU/mL qHBsAg decline by week 24 in 28% in TDF + PegIFN compared with 6% in TDF ( P = 0.04). HBsAg loss occurred in 7 of 12 (58%) with hepatitis B virus subgenotype A2 (all HBeAg positive) compared with only 2 of 189 (1%) with other hepatitis B virus genotypes and in 8 of 93 (8.6%) HBeAg positive vs 1 of 87 (1.1%) HBeAg negative. DISCUSSION: PegIFN combined TDF followed by protocolized TDF withdrawal led to earlier but not higher percentages of HBsAg clearance. Pretreatment HBeAg positivity and subgenotype A2 were strongly associated with HBsAg clearance.
Factors influencing post-surgical survival in degenerative mitral regurgitation
Butcher, Steele C. , Essayagh, Benjamin , Benfari, Giovanni , Antoine, Clémence , Roussel, Jean‐Christian , Wijngaarden, Aniek Van, Tribouilloy, Christophe , Ruşinaru, Dan, Topilsky, Yan , Michelena, Héctor I. , Delgado, Victoria , Enriquez‐Sarano, Maurice , Topilsky, Yan , Benfari, Giovanni , Roussel, Jean-Christian , Tribouilloy, Christophe , Hochstadt, Aviram , Michelena, Hector I , Enriquez-Sarano, Maurice , Delgado, Victoria , Topilsky, Yan , Essayagh, Benjamin , Butcher, Steele C , Steyerberg, Ewout W. , Grigioni, Francesco , Tourneau, Thierry Le , Marsan, Nina Ajmone , Bax, Jeroen J.

Mayo Clinic

European Heart Journal | January 4, 2023 | Volume: 44 | Issue: 10 | Pages: 871-881

10.1093/eurheartj/ehad004 | PMID 36702625 Get It

Abstract Aims Indications for surgery in patients with degenerative mitral regurgitation (DMR) are increasingly liberal in all clinical guidelines but the role of secondary outcome determinants (left atrial volume index ≥60 mL/m2, atrial fibrillation, pulmonary artery systolic pressure ≥50 mmHg and moderate to severe tricuspid regurgitation) and their impact on post-operative outcome remain disputed. Whether these secondary outcome markers are just reflective of the DMR severity or intrinsically affect survival after DMR surgery is uncertain and may have critical importance in the management of patients with DMR. To address these gaps of knowledge the present study gathered a large cohort of patients with quantified DMR, accounted for the number of secondary outcome markers and examined their independent impact on survival after surgical correction of the DMR. Methods and results The Mitral Regurgitation International DAtabase-Quantitative registry includes patients with isolated DMR from centres across North America, Europe, and the Middle East. Patient enrolment extended from January 2003 to January 2020. All patients undergoing mitral valve surgery within 1 year of registry enrolment were selected. A total of 2276 patients [65 (55–73) years, 32% male] across five centres met study eligibility criteria. Over a median follow-up of 5.6 (3.6 to 8.7) years, 278 patients (12.2%) died. In a comprehensive multivariable Cox regression model adjusted for age, EuroSCORE II, symptoms, left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LV ESD) and DMR severity, the number of secondary outcome determinants was independently associated with post-operative all-cause mortality, with adjusted hazard ratios of 1.56 [95% confidence interval (CI): 1.11–2.20, P = 0.011], 1.78 (95% CI: 1.23–2.58, P = 0.002) and 2.58 (95% CI: 1.73–3.83, P < 0.0001) for patients with one, two, and three or four secondary outcome determinants, respectively. A model incorporating the number of secondary outcome determinants demonstrated a higher C-index and was significantly more concordant with post-operative mortality than models incorporating traditional Class I indications alone [the presence of symptoms (P = 0.0003), or LVEF ≤60% (P = 0.006), or LV ESD ≥40 mm (P = 0.014)], while there was no significant difference in concordance observed compared with a model that incorporated the number of Class I indications for surgery combined (P = 0.71). Conclusion In this large cohort of patients treated surgically for DMR, the presence and number of secondary outcome determinants was independently associated with post-surgical survival and demonstrated better outcome discrimination than traditional Class I indications for surgery. Randomised controlled trials are needed to determine if patients with severe DMR who demonstrate a cardiac phenotype with an increasing number of secondary outcome determinants would benefit from earlier surgery.
Prospective Observational Study of Pain Severity and Pain Interference Outcomes Following Percutaneous MRI-guided Laser Ablation or Cryoablation for Focal Painful Peripheral, Soft Tissue Vascular Malformations: 12-month Outcomes
Koepsel, Erica M. Knavel , Powell, Garret M. , Bendel, Emily C. , Howe-Clayton, Desirae L., Favazza, Christopher , Lu, Aiming , Anderson, Katelyn , Tollefson, Megha M. , Woodrum, David A. , Thompson, Scott M. , Bjarnason, Haraldur , Polites, Stephanie F. , Adamo, Daniel A.

Mayo Clinic

Journal of Vascular Anomalies | January 4, 2023 | Volume: 4 | Issue: 1 | Pages: e055

10.1097/jova.0000000000000055 Get It

Background: Percutaneous image-guided thermal ablation has emerged as a treatment option for vascular malformations (VM). However, prospective data on intermediate to long-term effectiveness with uniform follow-up are lacking. Purpose: To prospectively evaluate the 12-month pain severity and pain interference outcomes following percutaneous MRI-guided laser ablation and cryoablation of focal painful, peripheral soft tissue VM. Materials and Methods: Participants undergoing clinically indicated MRI-guided laser ablation and cryoablation for focal painful (worst pain ≥4 out of 10 on Visual Analog Scale), peripheral soft tissue vascular malformations (VM) were enrolled in an IRB-approved prospective, observational study after giving informed consent. Participants completed the Brief Pain Inventory questionnaire prior to ablation and 1, 3, 6, and 12-month postablation. Differences in pain severity and interference outcomes from baseline on a 0 to 10 scale were compared using a paired t-test. Results: Seventeen participants (15 female; mean age 28.3 ± 9.3 years) underwent 24 MRI-guided and monitored ablation sessions including laser (n = 21), cryoablation (n = 2), or both (n = 1) for treatment of painful slow-flow (n = 16) or high-flow (n = 1) VM. Median maximal VM diameter was 5.7 cm (range 1.1 to 31.0 cm). Mean (±SD) preablation worst pain score was 7.9 ± 1.4. There was a significant decrease in worst pain at 1-month postablation (–3.5 ± 2.9; P = .0007) that was sustained at 3 (–3.4 ± 3.2; P = .0007), 6 (–4.2 ± 3.6; P = .0003), and 12 months (–3.6 ± 3.9; P = .002), with similar results for average, current, and least pain scores. There was a significant improvement in pain interference outcomes at 12-month postablation: general activity (P = .018), walking ability (P = .008), work (P = .003), sleep (P = .007), and enjoyment of life (P = .033). Conclusions: These data suggest that MRI-guided and monitored thermal ablation is safe and provides early and sustained significant improvements in pain severity and pain interference outcomes during the first year of follow-up in participants with focal painful peripheral soft tissue VM.
The roles of proteases in prostate cancer
Koistinen, Hannu , Kovanen, Ruusu‐Maaria , Hollenberg, Morley D. , Dufour, Antoine , Radisky, Evette S. , Batra, Jyotsna , Clements, Judith A. , Hooper, John D. , Diamandis, Eleftherios P. , Rannikko, Antti , Mirtti, Tuomas , Stenman, Ulf-Håkan , Batra, Jyotsna , Clements, Judith , Hooper, John D , Diamandis, Eleftherios , Schilling, Oliver , Rannikko, Antti , Mirtti, Tuomas , Radisky, Evette S , Stenman, Ulf‐Håkan

Mayo Clinic

IUBMB Life | January 4, 2023 | Volume: 75 | Issue: 6 | Pages: 493-513

10.1002/iub.2700 | PMID 36598826 Get It

Abstract Since the proposition of the pro‐invasive activity of proteolytic enzymes over 70 years ago, several roles for proteases in cancer progression have been established. About half of the 473 active human proteases are expressed in the prostate and many of the most well‐characterized members of this enzyme family are regulated by androgens, hormones essential for development of prostate cancer. Most notably, several kallikrein‐related peptidases, including KLK3 (prostate‐specific antigen, PSA), the most well‐known prostate cancer marker, and type II transmembrane serine proteases, such as TMPRSS2 and matriptase, have been extensively studied and found to promote prostate cancer progression. Recent findings also suggest a critical role for proteases in the development of advanced and aggressive castration‐resistant prostate cancer (CRPC). Perhaps the most intriguing evidence for this role comes from studies showing that the protease‐activated transmembrane proteins, Notch and CDCP1, are associated with the development of CRPC. Here, we review the roles of proteases in prostate cancer, with a special focus on their regulation by androgens.
Lymphoid Interstitial Pneumonia (LIP) Revisited
Fraune, Christoph , Yi, Eunhee S. , Khoór, András , Kelemen, Katalin, Larsen, Brandon T. , Butt, Yasmeen M. , Ryu, Jay H. , Tazelaar, Henry D. , Ryu, Jay H , Churg, Andrew , Smith, Maxwell L. , Gotway, Michael B. , Tazelaar, Henry D.

Mayo Clinic

American Journal of Surgical Pathology | January 4, 2023 | Volume: 47 | Issue: 3 | Pages: 281-295

10.1097/pas.0000000000002014 | PMID 36597787 Get It

The use of lymphoid interstitial pneumonia (LIP) as a diagnostic term has changed considerably since its introduction. Utilizing a multi-institutional collection of 201 cases from the last 20 years that demonstrate features associated with the LIP rubric, we compared cases meeting strict histologic criteria of LIP per American Thoracic Society (ATS)/European Respiratory Society (ERS) consensus (“pathologic LIP”; n=62) with cystic cases fulfilling radiologic ATS/ERS criteria (“radiologic LIP”; n=33) and with other diffuse benign lymphoid proliferations. “Pathologic LIP” was associated with immune dysregulation including autoimmune disorders and immune deficiency, whereas “radiologic LIP” was only seen with autoimmune disorders. No case of idiopathic LIP was found. On histology, “pathologic LIP” represented a subgroup of 70% (62/88) of cases with the distinctive pattern of diffuse expansile lymphoid infiltrates. In contrast, “radiologic LIP” demonstrated a broad spectrum of inflammatory patterns, airway-centered inflammation being most common (52%; 17/33). Only 5 cases with radiologic cysts also met consensus ATS/ERS criteria for “pathologic LIP.” Overall, broad overlap was observed with the remaining study cases that failed to meet consensus criteria for “radiologic LIP” and/or “pathologic LIP.” These data raise concerns about the practical use of the term LIP as currently defined. What radiologists and pathologist encounter as LIP differs remarkably, but neither “radiologic LIP” nor “pathologic LIP” present with sufficiently distinct findings to delineate such cases from other patterns of diffuse benign lymphoid proliferations. As a result of this study, we believe LIP should be abandoned as a pathologic and radiologic diagnosis.
Primary Nephrotic Syndrome
Zand, Landan, Fervenza, Fernando C.

Mayo Clinic

Nephrology Self-Assessment Program | January 4, 2023 | Volume: 21 | Issue: 5 | Pages: 337-351

10.1681/nsap.00102022 Get It

Abstract P070: Volumetric parenchymal pattern analysis for breast cancer risk estimation
Cohen, Eric A. , Pantalone, Lauren , Mankowski, Walter C. , Nguyen, Alex Anh-Tu, Vachon, Celine M, Mankowski, Walter C , Maghsoudi, Omid Haji , Acciavatti, Raymond J. , Scott, Christopher G. , Winham, Stacey J. , Maidment, Andrew D. A. , McCarthy, Anne Marie , Conant, Emily F. , Kontos, Despina

Mayo Clinic

Cancer Prevention Research | January 4, 2023 | Volume: 16 | Issue: 1_Supplement | Pages: P070-P070

10.1158/1940-6215.precprev22-p070 Get It

Abstract Introduction: Mammographic breast density is among the strongest risk factors for breast cancer. However, breast density is typically assessed subjectively by the radiologist according to the Breast Imaging Reporting and Data System (BI-RADS) based on 2 dimensional (2D) digital mammography (DM) images. Digital breast tomosynthesis (DBT) is quickly replacing DM and allows more detailed volumetric imaging of the breast. Advances in radiomics, the high-throughput extraction of radiologic features, has enabled characterization of breast parenchymal complexity beyond breast density alone. The purpose of this study was to compare the performance of volumetric parenchymal pattern analysis from DBT and DM with conventional breast density measurement with respect to breast cancer risk estimation. Methods: We performed a case control study among women with concurrent DM and DBT screening (Selenia Dimensions, Hologic Inc.) at our institution between 3/2011-12/2014. Cases were diagnosed with breast cancer within 1 year of screening; controls were confirmed negative or benign at 1 year follow-up, matched on race (Black, White, other/unknown) and age (5-year bins). After exclusions for imaging artifacts, craniocaudal (CC) and mediolateral oblique (MLO) views for 187 cases and 737 controls, in six image formats were assessed: 1) raw (“FOR PROCESSING”) DM; 2) processed (“FOR PRESENTATION”) DM; 3) raw DBT central projection; 4) processed DBT central projection; 5) DBT central reconstructed slice; and 6) DBT reconstructed stack. For cases, we analyzed the breast contralateral to cancer diagnosis; for controls the same breast as the matched case. We extracted radiomic features using a lattice-based approach with the publicly available CaPTk software, averaging features for each breast over CC and MLO views. We examined 3 lattice window sizes (6.4, 12.8, and 25.6 mm) and 23 resolutions for image resampling (0.075 - 2mm). We performed PCA on the resulting 487 features for each combination of window size and resolution and built conditional logistic regression models to assess the association of the first 7 principal components with breast cancer, with models including age, BMI, and BI-RADS density. For each image type we calculated the model C-statistic at all window sizes and resolutions, for a total of 2304 experimental conditions. Results: Features from reconstructed DBT scans had on average higher C-statistics across all experimental conditions. A model using only age, BMI, and BI-RADS density had a C-statistic of 0.61. Models using radiomic features plus age, BMI, and BI-RADS density had mean C-statistic of 0.68 (IQR 0.68, 0.69) for reconstructed DBT scans; for all other image types, the mean C-statistic ranged from 0.64 to 0.66. Conclusions: Incorporating volumetric breast parenchymal patterns from DBT improves breast cancer risk estimation beyond markers derived from DM and beyond conventional BI-RADS density. Citation Format: Eric A. Cohen, Omid Haji Maghsoudi, Raymond Acciavatti, Lauren Pantalone, Walter Mankowski, Alex A Nguyen, Christopher G. Scott, Stacey Winham, Andrew D. Maidment, Anne Marie McCarthy, Celine M Vachon, Emily F Conant, Despina Kontos. Volumetric parenchymal pattern analysis for breast cancer risk estimation. [abstract]. In: Proceedings of the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer; 2022 Nov 17-19; Austin, TX. Philadelphia (PA): AACR; Can Prev Res 2023;16(1 Suppl): Abstract nr P070.
Abstract P056: Germline cancer susceptibility gene testing in unselected patients with soft tissue sarcoma: a multi-center prospective study
Ailts, Isaak , Golafshar, Michael A. , Klint, Margaret, Barrus, Kathleen , Nussbaum, Samuel R., Leach, Brandie, Young, Sarah , Samadder, N. Jewel , Seetharam, ­Mahesh , Golafshar, Michael , Kunze, Katie L. , Esplin, Edward D. , Leach, Brandie

Mayo Clinic

Cancer Prevention Research | January 4, 2023 | Volume: 16 | Issue: 1_Supplement | Pages: P056-P056

10.1158/1940-6215.precprev22-p056 Get It

Abstract Sarcomas are rare heterogenous mesenchymal tumors with over 75 different subtypes, with varying biology and outcomes, with no clear inciting factor in the vast majority. The germline genetic susceptibility to sarcoma is not very well characterized. Identification of any underlying germline predisposition can have important implications for treatment of patients and screening recommendations for family members. To determine the prevalence of pathogenic germline variants (PGV) in patients with sarcomas, we undertook the Interrogating Cancer Etiology Using Proactive Genetic Testing (INTERCEPT) study, a prospective multi-site study of germline sequencing using a >80-gene next-generation sequencing platform. The study was done at the three Mayo Clinic Cancer Centers between April 1, 2018, and March 31, 2020. Patients were not selected based on stage, family cancer history, ethnicity, or age. Family cascade testing was offered at no charge. Results: 115 adult patients with soft tissue sarcoma were included in the study. The median age was 60 years, 58.5% were male, 81% were White. The anatomical location of the primary tumor included extremities (33.0%), retroperitoneum (18.2%), trunk (12.2%), head and neck (7.8%). Family history of cancer was present in 63% of the study population. Ten patients (8.7%) had a PGV. Thirty percent of the patients with PGV had stage IV sarcoma (3/10), and 70% (7/10) had earlier stage sarcoma (stages I-III). Among patients who were found to have a variant of uncertain significance (VUS), 40% (22/55) had stage IV sarcoma and 60% (33/55) had earlier stage disease. Of the 10 patients with PGV, high to medium penetrance gene abnormalities were identified in 8 patients (80%) involving TP53 (3), BRCA1 (1), SDHA (1), ATM (2) and heterozygous deletion of NBN (1) genes. Of these PGV, gene deletions were observed in 6/10 while missense variants comprised the remaining 4. The vast majority of the PGV (70%) would not have been identified using the current guidelines utilizing the 2018 or 2020 National Comprehensive Cancer Network (NCCN), National Society of Genetic Counselors (NSGC) or American College of Medical Genetics and Genomics. Conclusion: In this prospective, multi-site study comprising over 100 patients with diverse sarcomas, unselected germline testing identified a PGV in 1 in 11 patients (8.7%) with the majority of these not being detected using current standard of care guidelines for genetic testing. Because of the rarity of sarcomas, in addition to limited effective treatment options for advanced disease, large scale germline testing in sarcomas represents a potentially impactful strategy to assess therapeutic options and for assessment of familial risk. Citation Format: Isaak Ailts, Michael A. Golafshar, Katie L. Kunze, Margaret Klint, Kathleen Barrus, Samuel Nussbaum, Edward Esplin, Brandie Leach, Sarah Young, Niloy Jewel Samadder, Mahesh Seetharam. Germline cancer susceptibility gene testing in unselected patients with soft tissue sarcoma: a multi-center prospective study. [abstract]. In: Proceedings of the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer; 2022 Nov 17-19; Austin, TX. Philadelphia (PA): AACR; Can Prev Res 2023;16(1 Suppl): Abstract nr P056.
Abstract PR002: A pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer
Finn, Olivera J. , Krpata, Tami, Fatis, Samantha, McKolanis, John , Xue, Jia, Beatty, Pamela , Jacqueline, Camille M. , Kaufman, Sharon, Akerley, Colleen, Felt, April, Fursa, Karrie, Ambulay, Liz S., Foster, Nathan R. , Salazar, Andres Μ. , Bengtson, Lisa, Midthun, David E. , Pennathur, Arjun , Ward, Julie Ann , Holland, Anne Elizabeth , McMurray, Ryan P. , Strand, Carrie , Szabó, Éva , Limburg, Paul J. , Wojtowicz, Malgorzata E.

Mayo Clinic

Cancer Prevention Research | January 4, 2023 | Volume: 16 | Issue: 1_Supplement | Pages: PR002-PR002

10.1158/1940-6215.precprev22-pr002 Get It

Abstract Background: Smoking is the most common etiology for lung cancer and smoking cessation does not eliminate the risk. An emerging area of interest for risk reduction is immunoprevention. MUC1 glycoprotein is aberrantly expressed in adenocarcinomas, including lung cancer and their premalignant lesions. MUC1 vaccine in the premalignant or high-risk setting may be effective in halting neoplastic development and progression. Trial design: Through the NCI-funded Cancer Prevention Network (CPN), we conducted a two-center pilot trial to evaluate immunogenicity of the MUC1 vaccine (assessed at 12 weeks), and safety (assessed at up to 24 weeks) in current and former heavy smokers. 87 participants were screened in order to have at least 40 evaluable for baseline and 12-week immunogenicity assessments. Smoking history of ≥30 pack-years and either current (still smoking or quit < 1 year prior to pre-registration) or former smoker (quit 1-15 years prior to pre-registration); ages 55-80 years; ECOG performance status ≤1; CT scan of the chest done ≤ 6 months prior to pre-registration showing either negative findings (no nodules) or solid or part-solid nodules < 6 mm in size (consistent with < 1% probability of malignancy, Lung-RADs Version 1.0). Exclusion criteria were standard for lung cancer screening. Methods: MUC1 peptide plus polyICLC adjuvant (Hiltonol) vaccine was given at week 0, 2 and 10. Blood was collected for safety tests and immune assays pre and 2 weeks post each vaccine, and at week 24. Anti-MUC1 IgG titer was evaluated by ELISA. Based on previous studies of this vaccine, 40 evaluable participants would provide 96% power to detect immune response rate of 15% versus 40%, using a 2-sided test of proportions with type I error rate of 0.05. PBMC were assayed for the presence of regulatory T cells (Treg) and myeloid derived suppressor cells (MDSC) (secondary endpoint). Circulating levels of inflammatory cytokines and hsCRP were evaluated using commercially available tests (exploratory endpoint). AEs and toxicities were monitored for up to 24 weeks from the first vaccine. Results: 87 individuals were screened and 50 registered. 45 completed the study, 26 current and 19 former smokers (time since last smoked: average 7.8 years; 11 months -13 years). The vaccine was well-tolerated with injection site reactions being the most common AE. Immune response to the vaccine was lower than expected, with 2 current and 2 former smokers developing anti-MUC1 IgG titers ≥2 fold higher at week 12 over baseline (10%). We found high circulating levels of MDSCs in PBMC of both current and former smokers and very low or no serum cytokines. Conclusions: A preventative vaccine trial was feasible in individuals at high risk for lung cancer. However, we discovered a high level of immune suppression, previously documented only in advanced lung cancer. Mitigating the development of lung cancer in heavy smokers through vaccine administration may be limited by related immunosuppression. Citation Format: Olivera J. Finn, Julie Ward, Tami Krpata, Samantha Fatis, John McKolanis, Jia Xue, Pamela Beatty, Camille Jacqueline, Sharon Kaufman, Colleen Akerley, April Felt, Karrie Fursa, Anne Holland, Liz S. Ambulay, Nathan Foster, Ryan McMurray, Carrie Strand, Andres M. Salazar, Lisa Bengtson, Eva Szabo, Paul Limburg, Malgorzata Wojtowicz, David E. Midthun, Arjun Pennathur. A pilot study of a MUC1 vaccine in current and former smokers at high risk for lung cancer. [abstract]. In: Proceedings of the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer; 2022 Nov 17-19; Austin, TX. Philadelphia (PA): AACR; Can Prev Res 2023;16(1 Suppl): Abstract nr PR002.
Acne incidence in preadolescents and association with increased body mass index: A population‐based retrospective cohort study of 643 cases with age‐ and sex‐matched community controls
Baisi, Katinna E. Rodriguez , Weaver, Amy L. , Shakshouk, Hadir , Tollefson, Megha M. , Rodriguez Baisi, Katinna , Shakshouk, H

Mayo Clinic

Pediatric Dermatology | January 4, 2023 | Volume: 40 | Issue: 3 | Pages: 428-433

10.1111/pde.15223 | PMID 36597586 Get It

AbstractBackground/ObjectivesLittle is known about acne incidence in preadolescents and its potential association with body mass index (BMI). Our study aims to determine acne incidence in preadolescents and its association with BMI.MethodsA population‐based retrospective cohort study identified 7‐ to ≤12 year‐olds with an initial acne diagnosis during 2010–2018, and incidence was calculated. Two age‐ and sex‐matched controls without acne were randomly selected per case, and BMI was recorded.ResultsA total of 643 acne patients were identified. Annual age‐ and sex‐adjusted incidence rate was 58.0 per 10,000 person‐years, higher in females vs. males (89.2 vs. 28.2 per 10,000 person‐years, p < .001), and increased with age (4.3, 24.4, and 144.3 per 10,000 person‐years among 7–8, 9–10, and 11–12 year‐olds, respectively, p < .001). Systemic medication use was associated with increasing BMI (odds ratio = 1.43 per 5 kg/m2 increase in BMI, 95% CI 1.07–1.92, p = .015). Median BMI percentile was higher among acne cases vs. controls (75.0 vs. 65.0, p < .001), as was the proportion with BMI ≥95th percentile (16.7% vs. 12.2%, p = .01).ConclusionAcne incidence is higher in preadolescent girls than boys and increases with age. Preadolescents with acne are more likely to be obese than those without acne. Those with higher BMIs are more likely to be given systemic treatment.